Ganot Capital

Notal Vision, Inc. is a diagnostic services company focused on enhancing the management of eye diseases, particularly age-related macular degeneration, by facilitating home-based monitoring for patients. Founded in 2000, the company is headquartered in Manassas, Virginia, with an additional office in Tel Aviv, Israel. Notal Vision develops a cloud-based platform that offers a variety of tools, including ForeseeHome, an at-home monitoring device that detects and characterizes visual disturbances, and the Notal OCT Analyzer, which employs image analysis algorithms for the automated detection of pathological fluid in retinal diseases. The company also utilizes AI algorithms to provide diagnostic decision support, enabling patients to engage in testing and treatment in collaboration with their eye care providers. By extending eye disease management beyond the clinical setting, Notal Vision aims to improve visual outcomes for patients.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

Notal Vision, Inc. is a diagnostic services company focused on enhancing the management of eye diseases, particularly age-related macular degeneration, by facilitating home-based monitoring for patients. Founded in 2000, the company is headquartered in Manassas, Virginia, with an additional office in Tel Aviv, Israel. Notal Vision develops a cloud-based platform that offers a variety of tools, including ForeseeHome, an at-home monitoring device that detects and characterizes visual disturbances, and the Notal OCT Analyzer, which employs image analysis algorithms for the automated detection of pathological fluid in retinal diseases. The company also utilizes AI algorithms to provide diagnostic decision support, enabling patients to engage in testing and treatment in collaboration with their eye care providers. By extending eye disease management beyond the clinical setting, Notal Vision aims to improve visual outcomes for patients.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

Kyma Medical Technologies is an early-stage medical device company focused on cardiovascular diagnostics. Founded in March 2008, the company is developing a dual modality non-invasive diagnostic system designed to detect in-stent restenosis. Additionally, Kyma is working on a remote patient monitoring solution specifically for patients with congestive heart failure. This device includes a small patch that adheres to the patient's torso and wirelessly transmits health data to a remote monitoring center via a gateway device, such as a smartphone. Through these innovations, Kyma aims to enhance the management and monitoring of cardiovascular conditions.